An observational study in Scalp Psoriasis, Pustular Palmo-plantar Psoriasis and Non-pustular Palmo-plantar Psoriasis, sponsored by Innovaderm Research Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-27.
Sponsored by Innovaderm Research Inc. · Observational
The goal of this project is to study some mechanisms involved in the dysregulation of the immune system observed in the skin of subjects with psoriasis. This will be done by analyzing specific immune cells as well as gene and protein expression in small skin samples (biopsies) from patients with psoriasis. These results will be compared to the skin of healthy subjects without psoriasis.
A total of 80 subjects with psoriasis not currently using systemic treatment, with at least one psoriatic plaque on the trunk or proximal limbs and having also more resistant to treat psoriasis areas will be recruited. These subjects will be classified in the following 5 groups according to the localization of resistant areas: scalp psoriasis (20 subjects), pustular palmo-plantar psoriasis (10 subjects), non-pustular palmo-plantar psoriasis (10 subjects), elbow psoriasis (20 subjects) and lower leg psoriasis (20 subjects).
At Day 0 visit, severity of psoriasis will be evaluated using the body surface area (BSA) and the Psoriasis Area and Severity Index (PASI).
After appropriate washout periods, all 80 subjects will have two skin biopsies: one from a plaque located on the trunk or proximal limbs and one on a plaque located on an area more resistant to treatment (scalp, palms/soles, elbow or lower leg). Each biopsy will be split in half. One part will be used for a limited immunohistochemistry panel and additional staining will be performed on samples from the pustular palmo-plantar psoriasis and non-pustular palmo-plantar psoriasis subjects to localize IL-17A and IL-23 producing cells. The other half will be used for gene expression analysis using Reverse-Transcription-Polymerase Chain Reaction (RT-PCR) for all subjects including the following genes: IL-23 (p40 \& p19), IL-17A and Human Acidic Ribosomal Protein (HARP). In addition, the expression of other specific genes of interest will be analyzed using RT-PCR for subjects with pustular palmo-plantar psoriasis and non-pustular palmo-plantar psoriasis. Moreover, four skin biopsies will be collected from 10 healthy volunteers for RT-PCR (IL-23 (p40 \& p19), IL-17A and HARP). One biopsy will be collected from the trunk and another one from a palm or a sole. A third and a fourth biopsy will be collected on additional areas (scalp, elbow or lower limb). Gene expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) will be compared to gene expression in plaques from the trunk or other areas of the upper and lower limbs.
A total of 30 subjects out of 80 will also have one or two additional skin biopsies. The 10 subjects with pustular palmo-plantar psoriasis and 10 subjects with non-pustular palmo-plantar psoriasis will have one additional biopsy of the involved skin of the palm and one of a plaque on the trunk or limbs for cell isolation and cell analysis in order to explore the mechanisms involved in the increased expression of IL-17A without concurrent increase in IL-23. Ten subjects with psoriasis vulgaris on the trunk or upper limbs but without pustular or non-pustular palmo-plantar psoriasis will also have an additional biopsy performed on lesional skin. Following inflammatory cells extraction, flow cytometry combining cell surface markers and intra-cytoplasmic staining will be used to study IL-17A and IL-23 in T cells, granulocytes/mastocytes/macrophages and Ag-presenting cells. If enough cells are harvested, three antibody panels will be analyzed in the following order using flow cytometry: a T cell panel, a granulocytes / mastocytes / macrophages panel and an antigen presenting cell (APC) panel. All panels with also be evaluated with an anti-CD45 (cluster of differentiation) antibody and a viability test (Aqua live/dead). Results from flow cytometry will be compared for biopsies from palms of subjects with pustular and non-pustular palmo-plantar psoriasis, trunk or proximal limbs of subjects with pustular and non-pustular palmo-plantar psoriasis and trunk or proximal limbs of subjects with psoriasis vulgaris.
All skin biopsies will be performed at Day 0 visit and an optional study visit (Day 10) will be performed if suture removal from skin biopsies is necessary.
In addition, circulating plasma levels of IL-17A will be measured for all subjects and healthy volunteers in order to compare IL-17A levels in the 5 groups of subjects with psoriasis and healthy subjects. Moreover, correlation between IL-17A levels and PASI will be explored.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's planned enrollment of 90 is below the median of 200 across 396 observational studies indexed under Psoriasis.
Browse Psoriasis studies →Innovaderm Research Inc. is the lead sponsor of 34 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Invitation to volunteer
Female subject is willing to use effective contraceptive method for at least 30 days before Day 0 and at least until Day 10. Effective contraceptive methods are:
Exclusion Criteria:
Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
Source of IL 17A
Explore the cellular source of IL 17A and mechanisms involved in the higher IL 17A/IL 23 expression ratio observed in palmo plantar skin of subjects with psoriasis
Time frame: Day 0
Mechanism involved in the IL 17A/IL 23 expression ratio
Explore the cellular source of IL 17A and mechanisms involved in the higher IL 17A/IL 23 expression ratio observed in palmo plantar skin of subjects with psoriasis
Time frame: Day 0
Compare IL 17A expression in plaques from scalp against plaques from trunk or lower limbs
Compare IL 17A and IL 23 expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) to expression in plaques from the trunk or other areas of the upper and lower limbs
Time frame: Day 0
Compare IL 23 expression in plaques from scalp against plaques from trunk or lower limbs
Compare IL 17A and IL 23 expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) to expression in plaques from the trunk or other areas of the upper and lower limbs
Time frame: Day 0
Compare IL 17A expression in plaques from palms against plaques from trunk or lower limbs
Compare IL 17A and IL 23 expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) to expression in plaques from the trunk or other areas of the upper and lower limbs
Time frame: Day 0
Compare IL 23 expression in plaques from palms against plaques from trunk or lower limbs
Compare IL 17A and IL 23 expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) to expression in plaques from the trunk or other areas of the upper and lower limbs
Time frame: Day 0
Compare IL 17A expression in plaques from elbows against plaques from trunk or lower limbs
Compare IL 17A and IL 23 expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) to expression in plaques from the trunk or other areas of the upper and lower limbs
Time frame: Day 0
Compare IL 23 expression in plaques from elbows against plaques from trunk or lower limbs
Compare IL 17A and IL 23 expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) to expression in plaques from the trunk or other areas of the upper and lower limbs
Time frame: Day 0
Compare IL 17A expression in plaques from lower legs against plaques from trunk or lower limbs
Compare IL 17A and IL 23 expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) to expression in plaques from the trunk or other areas of the upper and lower limbs
Time frame: Day 0
Compare IL 23 expression in plaques from lower legs against plaques from trunk or lower limbs
Compare IL 17A and IL 23 expression in plaques from areas more resistant to treatment (scalp, palms, elbows, lower legs) to expression in plaques from the trunk or other areas of the upper and lower limbs
Time frame: Day 0
IL 17A plasma levels of patients with scalp psoriasis
Compare plasma levels of IL 17A among the 5 groups of subjects with psoriasis in areas that are more resistant to treat and healthy subjects
Time frame: Day 0
IL 17A plasma levels of patients with pustular palmo-plantar psoriasis
Compare plasma levels of IL 17A among the 5 groups of subjects with psoriasis in areas that are more resistant to treat and healthy subjects
Time frame: Day 0
IL 17A plasma levels of patients with elbow psoriasis
Compare plasma levels of IL 17A among the 5 groups of subjects with psoriasis in areas that are more resistant to treat and healthy subjects
Time frame: Day 0
IL 17A plasma levels of patients with lower leg psoriasis
Compare plasma levels of IL 17A among the 5 groups of subjects with psoriasis in areas that are more resistant to treat and healthy subjects
Time frame: Day 0
IL 17A plasma levels of patients with non-pustular palmo-plantar psoriasis
Compare plasma levels of IL 17A among the 5 groups of subjects with psoriasis in areas that are more resistant to treat and healthy subjects
Time frame: Day 0
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innovaderm Research Inc.